Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1985;86(3):281-5.
doi: 10.1007/BF00432214.

Aversive properties of naloxone in non-dependent (naive) rats may involve blockade of central beta-endorphin

Aversive properties of naloxone in non-dependent (naive) rats may involve blockade of central beta-endorphin

R F Mucha et al. Psychopharmacology (Berl). 1985.

Abstract

The present study examines the influence of destruction of the medio-basal arcuate hypothalamus (MBH), the primary site of synthesis of central pools of beta-endorphin (beta-EP), upon the aversive properties of naloxone in a conditioned place preference paradigm. Bilateral radiofrequency lesions of the MBH resulted in a pronounced fall in levels of immunoreactive beta-EP in the brain. Lesioned rats, in contrast to non-operated animals, showed a clear reduction in the conditioned place aversion produced by naloxone. However, they showed no loss of the conditioned preference produced by the mu-selective opioid receptor agonist, morphine, or the conditioned aversion produced by the kappa-selective agonist, U50-488. In contrast to the effect of the lesions, suppression of circulating beta-EP by dexamethasone treatment failed to influence conditioning produced by naloxone. Thus, the data indicate that the aversive properties of naloxone are attenuated by disruption of central (but not peripheral) beta-EP activity. We suggest that these properties of naloxone reflect an antagonism of beta-EP activity in the brain. In addition, the data indicate that differing mechanisms underlie the aversive actions of naloxone as compared to U50-488.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Brain Res. 1982 Jul 8;243(1):107-17 - PubMed
    1. Neuroendocrinology. 1981 Jul;33(1):28-42 - PubMed
    1. J Pharmacol Exp Ther. 1979 Oct;211(1):50-8 - PubMed
    1. Science. 1977 Sep 30;197(4311):1367-9 - PubMed
    1. Brain Res. 1977 Jan 14;120(1):151-7 - PubMed

Publication types

LinkOut - more resources